SynthesisBlood advances2019
Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.
Synthesis in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05004259 (The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes.American journal of hematology · 2025Pooled it
- Global, Regional and National Burden of Hemolytic Disease and Other Neonatal Jaundice, 1980/90-2021, and Projections to 2050: A Global Burden of Disease Study 2021.Health science reports · 2026Article
- Bone Marrow Pathology in Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia: A Study of 56 Cases.European journal of haematology · 2026Article
- A Case Report of a 14-year-old Boy with Mixed-type Autoimmune Hemolytic Anemia.Annals of African medicine · 2026Article
- Novel insights from a large cohort: Elucidating incidence, risk factors, treatment, and prognostic predictors in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.Journal of translational internal medicine · 2026Article
- Treating hematologic immune dysregulation in inborn errors of immunity: a real-life multicenter study.Frontiers in immunology · 2026Article
- Construction of a predictive model for relapse of primary autoimmune hemolytic anemia: a retrospective cohort study.Annals of medicine · 2025Article
- Cold versus warm autoimmune hemolytic anemia in diffuse large B cell lymphoma: pathogenic and therapeutic implications: a case series.Journal of medical case reports · 2025Article
- Refractory cold autoimmune hemolytic anemia as initial presentation of gastric B cell lymphoma: a case report.Journal of medical case reports · 2025Article
- Prediction of thrombotic events in patients with autoimmune hemolytic anemia: a multicenter retrospective observational study.Journal of thrombosis and thrombolysis · 2025Observational
- Real-World Use of Rituximab in the Treatment of Cold Agglutinin Disease in the United States: A Retrospective Study.EJHaem · 2025Article
- Treatment and clinical outcomes of pediatric autoimmune hemolytic anemia: real-world single-center data from Korea.Clinical and experimental pediatrics · 2025Article
- Exploring Protein A Immunoadsorption for Autoimmune Hemolytic Anemia with Hyper-IgG4emia.The American journal of case reports · 2025Article
- New-onset hematologic disorders following COVID-19 vaccination: a systematic review.Clinical and experimental vaccine research · 2025Article
- Efficacy and Safety of Weekly Bortezomib-dexamethasone as the Third-Line Therapy for Warm Autoimmune Hemolytic Anemia: a Case Series of 5 Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review.Frontiers in immunology · 2025Article
- Case Report: SevereFrontiers in immunology · 2025Article
- Respiratory Syncytial Virus (RSV)-Induced Autoimmune Hemolytic Anemia Presenting as Syncope: A Case Report.Cureus · 2025Article
- Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy.Current oncology reports · 2024Review
- Splenectomy outcomes in immune cytopenias: Treatment outcomes and determinants of response.Journal of internal medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The terminology applied to autoimmune hemolytic anemia (AIHA) seems inconsistent. We aimed to evaluate the consistency of definitions used for diagnosis and treatment. In this systematic review of literature from January 2006 to December 2015, we assessed heterogeneity in the definition of AIHA and its subtypes, refractory disease, disease phase, severity, criteria for treatment response, and response durability. A Medline search for anemia, hemolytic, autoimmune was supplemented with keyword searches. Main exclusions were conference abstracts, animal and non-English studies, and studies with <10 cases. Of 1371 articles retrieved, 1209 were excluded based on titles and abstracts. Two authors independently reviewed 10% and 16% of abstracts and full papers, respectively. After full-paper review, 84 studies were included. AIHA was most frequently (32 [52%] of 61) defined as hemolytic anemia with positive direct antiglobulin test (DAT) and exclusion of alternatives, but 10 of 32 also recognized DAT-negative AIHA. A lower threshold for diagnosis of DAT-negative AIHA was observed in literature on chronic lymphocytic leukemia. Definitions of anemia, hemolysis, and exclusion criteria showed substantial variation. Definitions of primary/secondary cold agglutinin disease/syndrome were not consistent. Forty-three studies provided criteria for treatment response, and other than studies from 1 center, these were almost entirely unique. Other criteria were rarely defined. Only 7, 0, 3, 2, 2, and 3 studies offered definitions of warm AIHA, paroxysmal cold hemoglobinuria, mixed AIHA, AIHA severity, disease phase, and refractory AIHA, respectively. Marked heterogeneity in the time period sampled indicates the need to standardize AIHA terminology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.